Alkem Laboratories Limited (ALKEM) - Net Assets

Latest as of September 2025: Rs138.11 Billion INR ≈ $1.49 Billion USD

Based on the latest financial reports, Alkem Laboratories Limited (ALKEM) has net assets worth Rs138.11 Billion INR (≈ $1.49 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs202.87 Billion ≈ $2.19 Billion USD) and total liabilities (Rs64.77 Billion ≈ $700.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALKEM tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs138.11 Billion
% of Total Assets	68.08%
Annual Growth Rate	16.83%
5-Year Change	64.51%
10-Year Change	228.33%
Growth Volatility	13.93

Alkem Laboratories Limited - Net Assets Trend (2010–2025)

This chart illustrates how Alkem Laboratories Limited's net assets have evolved over time, based on quarterly financial data. See how many days can Alkem Laboratories Limited fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Alkem Laboratories Limited (2010–2025)

The table below shows the annual net assets of Alkem Laboratories Limited from 2010 to 2025. For live valuation and market cap data, see ALKEM stock market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs124.34 Billion ≈ $1.34 Billion	+16.05%
2024-03-31	Rs107.14 Billion ≈ $1.16 Billion	+13.56%
2023-03-31	Rs94.35 Billion ≈ $1.02 Billion	+6.64%
2022-03-31	Rs88.47 Billion ≈ $956.81 Million	+17.06%
2021-03-31	Rs75.58 Billion ≈ $817.37 Million	+19.80%
2020-03-31	Rs63.09 Billion ≈ $682.29 Million	+13.23%
2019-03-31	Rs55.72 Billion ≈ $602.59 Million	+11.77%
2018-03-31	Rs49.85 Billion ≈ $539.14 Million	+8.78%
2017-03-31	Rs45.83 Billion ≈ $495.62 Million	+21.02%
2016-03-31	Rs37.87 Billion ≈ $409.55 Million	+22.77%
2015-03-31	Rs30.85 Billion ≈ $333.60 Million	+16.18%
2014-03-31	Rs26.55 Billion ≈ $287.14 Million	+11.85%
2013-03-31	Rs23.74 Billion ≈ $256.72 Million	+24.58%
2012-03-31	Rs19.06 Billion ≈ $206.08 Million	+63.22%
2011-03-31	Rs11.67 Billion ≈ $126.25 Million	-3.14%
2010-03-31	Rs12.05 Billion ≈ $130.35 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Alkem Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 10641.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs99.73 Billion	83.21%
Common Stock	Rs239.10 Million	0.20%
Other Comprehensive Income	Rs19.88 Billion	16.59%
Total Equity	Rs119.85 Billion	100.00%

Alkem Laboratories Limited Competitors by Market Cap

The table below lists competitors of Alkem Laboratories Limited ranked by their market capitalization.

Company	Market Cap
JSW Infrastructure Limited NSE:JSWINFRA	$6.95 Billion
SODEXO S.A. ADR/ 1/5 EO 4 F:SJ70	$6.95 Billion
SIGMASTAR TECH LTD SHE:301536	$6.95 Billion
Nedbank Group Ltd JSE:NED	$6.96 Billion
Shanghai Electric Power Co Ltd SHG:600021	$6.95 Billion
Synovus Financial Corp NYSE:SNV	$6.95 Billion
Technology One Ltd AU:TNE	$6.94 Billion
Dpm Metals Inc. AU:DPM	$6.94 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Alkem Laboratories Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 103,120,600,000 to 119,848,700,000, a change of 16,728,100,000 (16.2%).
Net income of 21,654,800,000 contributed positively to equity growth.
Dividend payments of 5,046,200,000 reduced retained earnings.
Other comprehensive income increased equity by 95,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs21.65 Billion	+18.07%
Dividends Paid	Rs5.05 Billion	-4.21%
Other Comprehensive Income	Rs95.00 Million	+0.08%
Other Changes	Rs24.50 Million	+0.02%
Total Change	Rs-	16.22%

Book Value vs Market Value Analysis

This analysis compares Alkem Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.36x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 53.31x to 5.36x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-03-31	Rs100.80	Rs5373.50	x
2011-03-31	Rs119.39	Rs5373.50	x
2012-03-31	Rs159.37	Rs5373.50	x
2013-03-31	Rs198.54	Rs5373.50	x
2014-03-31	Rs222.06	Rs5373.50	x
2015-03-31	Rs250.83	Rs5373.50	x
2016-03-31	Rs308.78	Rs5373.50	x
2017-03-31	Rs373.66	Rs5373.50	x
2018-03-31	Rs406.79	Rs5373.50	x
2019-03-31	Rs454.93	Rs5373.50	x
2020-03-31	Rs515.26	Rs5373.50	x
2021-03-31	Rs616.96	Rs5373.50	x
2022-03-31	Rs722.44	Rs5373.50	x
2023-03-31	Rs756.52	Rs5373.50	x
2024-03-31	Rs862.46	Rs5373.50	x
2025-03-31	Rs1002.36	Rs5373.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Alkem Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 18.07%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 16.91%
• Asset Turnover: 0.72x
• Equity Multiplier: 1.48x
Recent ROE (18.07%) is above the historical average (17.95%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	19.50%	17.49%	0.86x	1.29x	Rs1.15 Billion
2011	22.66%	19.57%	0.64x	1.81x	Rs1.81 Billion
2012	22.33%	22.17%	0.60x	1.67x	Rs2.35 Billion
2013	20.90%	21.79%	0.56x	1.71x	Rs2.59 Billion
2014	16.53%	14.27%	0.71x	1.64x	Rs1.73 Billion
2015	13.06%	10.55%	0.70x	1.77x	Rs916.85 Million
2016	20.09%	15.24%	0.88x	1.50x	Rs3.72 Billion
2017	19.97%	15.88%	0.86x	1.47x	Rs4.45 Billion
2018	12.97%	10.01%	0.82x	1.58x	Rs1.45 Billion
2019	13.98%	10.47%	0.89x	1.51x	Rs2.17 Billion
2020	18.29%	13.76%	0.82x	1.61x	Rs5.11 Billion
2021	21.49%	18.16%	0.76x	1.56x	Rs8.47 Billion
2022	19.05%	15.65%	0.75x	1.63x	Rs7.82 Billion
2023	10.88%	8.60%	0.83x	1.52x	Rs796.41 Million
2024	17.41%	14.44%	0.80x	1.51x	Rs7.65 Billion
2025	18.07%	16.91%	0.72x	1.48x	Rs9.67 Billion

Industry Comparison

This section compares Alkem Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $13,938,672,735
Average return on equity (ROE) among peers: 16.20%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Alkem Laboratories Limited (ALKEM)	Rs138.11 Billion	19.50%	0.47x	$6.95 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$334.70 Million	1.97%	2.20x	$25.64 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.23 Billion	12.93%	2.27x	$365.55 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$678.18 Million
Abbott India Limited (ABBOTINDIA)	$3.05 Billion	19.95%	0.50x	$6.02 Billion
Ajanta Pharma Limited (AJANTPHARM)	$2.98 Billion	25.93%	1.18x	$4.14 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$7.20 Billion	-0.56%	3.88x	$1.00 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.09 Billion	18.92%	0.29x	$170.48 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.62 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$37.76 Billion	41.73%	1.51x	$9.32 Billion

About Alkem Laboratories Limited

NSE:ALKEM India Drug Manufacturers - Specialty & Generic

Market Cap

$6.95 Billion

Rs642.48 Billion INR

Market Cap Rank

#2929 Global

#131 in India

Share Price

Rs5373.50

Change (1 day)

+0.03%

52-Week Range

Rs4732.80 - Rs5890.00

All Time High

Rs6366.25